Total Payments
$3,363
2024 Payments
$896.19
Companies
32
Transactions
177
Medicare Patients
3,049
Medicare Billing
$602,765
Payment Breakdown by Category
Food & Beverage$3,199 (95.1%)
Education$164.52 (4.9%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $3,199 | 162 | 95.1% |
| Education | $164.52 | 15 | 4.9% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | $389.01 | 27 | $0 (2024) |
| Otsuka America Pharmaceutical, Inc. | $346.86 | 19 | $0 (2024) |
| Amgen Inc. | $308.79 | 7 | $0 (2024) |
| Relypsa, Inc. | $307.02 | 20 | $0 (2020) |
| Mallinckrodt LLC | $226.01 | 13 | $0 (2018) |
| Fresenius USA Marketing, Inc. | $166.13 | 5 | $0 (2019) |
| AstraZeneca Pharmaceuticals LP | $151.94 | 9 | $0 (2024) |
| BARD PERIPHERAL VASCULAR, INC. | $148.70 | 1 | $0 (2019) |
| Travere Therapeutics, Inc. | $115.61 | 10 | $0 (2024) |
| Keryx Biopharmaceuticals, Inc. | $115.53 | 8 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $896.19 | 49 | Amgen Inc. ($258.86) |
| 2023 | $170.12 | 8 | Bayer Healthcare Pharmaceuticals Inc. ($40.96) |
| 2022 | $288.55 | 16 | Bayer HealthCare Pharmaceuticals Inc. ($91.79) |
| 2021 | $296.16 | 16 | GlaxoSmithKline, LLC. ($58.42) |
| 2020 | $167.16 | 9 | Relypsa, Inc. ($57.60) |
| 2019 | $540.13 | 24 | Otsuka America Pharmaceutical, Inc. ($154.79) |
| 2018 | $531.22 | 30 | Fresenius USA Marketing, Inc. ($148.58) |
| 2017 | $473.68 | 25 | Mallinckrodt LLC ($168.70) |
All Payment Transactions
177 individual payment records from CMS Open Payments — Page 1 of 8
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/13/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $19.34 | General |
| Category: Cardio-renal | ||||||
| 12/12/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $5.57 | General |
| Category: Cardio-renal | ||||||
| 12/10/2024 | Otsuka America Pharmaceutical, Inc. | JYNARQUE (Drug) | Food and Beverage | In-kind items and services | $20.13 | General |
| Category: NEPHROLOGY | ||||||
| 11/25/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $8.71 | General |
| Category: Cardio-renal | ||||||
| 11/25/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $3.54 | General |
| Category: Cardio-renal | ||||||
| 11/25/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $2.99 | General |
| Category: Cardio-renal | ||||||
| 11/14/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $28.12 | General |
| Category: Cardio-renal | ||||||
| 10/29/2024 | Novartis Pharmaceuticals Corporation | Fabhalta (Drug) | Food and Beverage | In-kind items and services | $14.55 | General |
| Category: Immunology | ||||||
| 10/04/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $11.97 | General |
| Category: Cardio-renal | ||||||
| 10/03/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $5.17 | General |
| Category: Cardio-renal | ||||||
| 10/02/2024 | Travere Therapeutics, Inc. | — | Food and Beverage | In-kind items and services | $17.48 | General |
| 10/02/2024 | Travere Therapeutics, Inc. | — | Food and Beverage | In-kind items and services | $1.75 | General |
| 10/01/2024 | Otsuka America Pharmaceutical, Inc. | JYNARQUE (Drug) | Food and Beverage | In-kind items and services | $21.53 | General |
| Category: NEPHROLOGY | ||||||
| 09/30/2024 | Vifor Pharma, Inc. | Veltassa (Drug) | Food and Beverage | In-kind items and services | $16.59 | General |
| Category: Hyperkalemia | ||||||
| 09/24/2024 | Amgen Inc. | TAVNEOS (Drug) | Food and Beverage | In-kind items and services | $95.72 | General |
| Category: Inflammation | ||||||
| 09/20/2024 | Kyowa Kirin, Inc. | Crysvita (Drug) | Food and Beverage | In-kind items and services | $22.48 | General |
| Category: fibroblast growth factor 23 (FGF23) blocking antibody. | ||||||
| 09/18/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $18.88 | General |
| Category: Cardio-renal | ||||||
| 09/18/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $7.74 | General |
| Category: Cardio-renal | ||||||
| 09/04/2024 | Travere Therapeutics, Inc. | — | Education | In-kind items and services | $2.38 | General |
| 09/03/2024 | Vifor Pharma, Inc. | Veltassa (Drug) | Food and Beverage | In-kind items and services | $13.66 | General |
| Category: Hyperkalemia | ||||||
| 08/21/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $24.24 | General |
| Category: Cardio-renal | ||||||
| 08/15/2024 | Travere Therapeutics, Inc. | — | Education | In-kind items and services | $2.38 | General |
| 08/09/2024 | Ardelyx, Inc. | IBSRELA (Drug) | Food and Beverage | In-kind items and services | $18.81 | General |
| Category: GASTROENTEROLOGY | ||||||
| 08/07/2024 | Amgen Inc. | TAVNEOS (Drug) | Food and Beverage | In-kind items and services | $24.41 | General |
| Category: Inflammation | ||||||
| 07/24/2024 | ANI Pharmaceuticals, Inc. | PURIFIED CORTROPHIN GEL (Drug) | Food and Beverage | In-kind items and services | $23.61 | General |
| Category: Treatment of certain chronic autoimmune disorders including acute exacerbations of MS and RA | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 9 | 806 | 1,881 | $277,602 | $172,534 |
| 2022 | 11 | 795 | 1,568 | $237,975 | $151,477 |
| 2021 | 10 | 646 | 1,384 | $212,381 | $139,602 |
| 2020 | 10 | 802 | 1,718 | $231,193 | $139,153 |
Total Patients
3,049
Total Services
6,551
Medicare Billing
$602,765
Procedure Codes
40
All Medicare Procedures & Services
40 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 236 | 1,034 | $95,128 | $62,916 | 66.1% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 195 | 236 | $59,472 | $31,322 | 52.7% |
| 90960 | Dialysis services, 4 or more physician visits per month (20 years or older) | Office | 2023 | 21 | 102 | $38,250 | $27,506 | 71.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 147 | 231 | $34,452 | $19,248 | 55.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 63 | 95 | $18,525 | $11,175 | 60.3% |
| 90961 | Dialysis services, 2-3 physician visits per month (20 years or older) | Office | 2023 | 14 | 30 | $9,150 | $6,723 | 73.5% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 37 | 37 | $9,324 | $5,578 | 59.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 69 | 75 | $7,930 | $4,310 | 54.3% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 24 | 41 | $5,371 | $3,756 | 69.9% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 218 | 703 | $64,676 | $38,622 | 59.7% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 167 | 190 | $47,880 | $28,893 | 60.3% |
| 90960 | Dialysis services, 4 or more physician visits per month (20 years or older) | Office | 2022 | 18 | 101 | $37,875 | $28,151 | 74.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 108 | 173 | $25,840 | $16,035 | 62.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 61 | 115 | $22,299 | $14,949 | 67.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 108 | 124 | $13,104 | $7,166 | 54.7% |
| 90961 | Dialysis services, 2-3 physician visits per month (20 years or older) | Office | 2022 | 17 | 31 | $9,455 | $7,160 | 75.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 27 | 28 | $7,056 | $4,615 | 65.4% |
| 90935 | Hemodialysis procedure with physician evaluation | Facility | 2022 | 29 | 55 | $4,950 | $3,054 | 61.7% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 16 | 20 | $3,440 | $1,990 | 57.8% |
| 99231 | Follow-up hospital inpatient care per day, typically 15 minutes | Facility | 2022 | 26 | 28 | $1,400 | $842.75 | 60.2% |
| 90960 | Dialysis services (4 or more physician visits per month), patient 20 years of age and older | Office | 2021 | 26 | 159 | $59,625 | $45,381 | 76.1% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 179 | 647 | $59,524 | $36,876 | 62.0% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 127 | 142 | $35,784 | $22,437 | 62.7% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 83 | 134 | $19,440 | $11,755 | 60.5% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 141 | 183 | $18,507 | $10,832 | 58.5% |
About Dr. Daniel Barton, MD
Dr. Daniel Barton, MD is a Nephrology healthcare provider based in Canfield, Ohio. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 02/28/2006. The National Provider Identifier (NPI) number assigned to this provider is 1063488096.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Daniel Barton, MD has received a total of $3,363 in payments from pharmaceutical and medical device companies, with $896.19 received in 2024. These payments were reported across 177 transactions from 32 companies. The most common payment nature is "Food and Beverage" ($3,199).
As a Medicare-enrolled provider, Barton has provided services to 3,049 Medicare beneficiaries, totaling 6,551 services with total Medicare billing of $602,765. Data is available for 4 years (2020–2023), covering 40 distinct procedure/service records.
Ad
Practice Information
- Specialty Nephrology
- Location Canfield, OH
- Active Since 02/28/2006
- Last Updated 12/23/2009
- Taxonomy Code 207RN0300X
- Entity Type Individual
- NPI Number 1063488096
Products in Payments
- Kerendia (Drug) $389.01
- Veltassa (Drug) $386.69
- ACTHAR (Biological) $336.49
- JYNARQUE (Drug) $311.27
- TAVNEOS (Drug) $171.58
- Auryxia (Drug) $135.25
- KRYSTEXXA (Biological) $131.55
- Velphoro (Drug) $122.57
- BENLYSTA (Biological) $106.28
- LOKELMA (Drug) $105.40
- SAMSCA (Drug) $89.80
- AVYCAZ (Drug) $70.22
- INJECTAFER (Drug) $48.63
- FARXIGA (Drug) $46.54
- GATTEX (Drug) $40.18
- FABRY-DISEASE (Drug) $39.09
- Ultomiris (Drug) $38.03
- SOLIRIS (Drug) $36.87
- IBSRELA (Drug) $34.87
- TARPEYO (Drug) $34.48
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.